Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Check Note
Ver. Summary Created by Modification Content Size Created at Operation
1 + 979 word(s) 979 2020-12-15 08:01:39
Upload a video

methylenetetrahydrofolate reductase

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 171
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 23 Dec 2020
Table of Contents

    1. Introduction

    The MTHFR gene provides instructions for making an enzyme called methylenetetrahydrofolate reductase. This enzyme plays a role in processing amino acids, the building blocks of proteins. Methylenetetrahydrofolate reductase is important for a chemical reaction involving the vitamin folate (also called vitamin B9). Specifically, this enzyme converts a form of folate called 5,10-methylenetetrahydrofolate to a different form of folate called 5-methyltetrahydrofolate. This is the primary form of folate found in blood, and is necessary for the multistep process that converts the amino acid homocysteine to another amino acid, methionine. The body uses methionine to make proteins and other important compounds.

    2. Health Conditions Related to Genetic Changes


    At least 40 mutations in the MTHFR gene have been identified in people with homocystinuria, a disorder in which the body is unable to process homocysteine and methionine properly. People with this condition often develop eye problems, abnormal blood clotting, skeletal abnormalities, and learning problems. Most of the mutations that cause homocystinuria change single amino acids in methylenetetrahydrofolate reductase. These changes impair the function of the enzyme, and some cause the enzyme to be turned off (inactivated). Other mutations lead to the production of an abnormally small, nonfunctional version of the enzyme. Without functional methylenetetrahydrofolate reductase, homocysteine cannot be converted to methionine. As a result, homocysteine builds up in the bloodstream, and the amount of methionine is reduced. Some of the excess homocysteine is excreted in urine (homocystinuria). Researchers have not determined how altered levels of homocysteine and methionine lead to the various health problems affecting multiple parts of the body in people with homocystinuria.

    2.2. Anencephaly

    Some studies have found that variations (polymorphisms) in the MTHFR gene have been associated with a small increased risk of neural tube defects, a group of birth defects that occur during the development of the brain and spinal cord. Anencephaly is one of the most common types of neural tube defect. Affected individuals are missing large parts of the brain and have missing or incompletely formed skull bones.

    The most well-studied MTHFR polymorphism changes a single DNA building block (nucleotide) in the MTHFR gene. Specifically, it replaces the nucleotide cytosine with the nucleotide thymine at position 677 (written as 677C>T). This common variant results in a form of methylenetetrahydrofolate reductase that has reduced activity at higher temperatures (the enzyme is thermolabile). People with the 677C>T polymorphism, particularly those with the genetic change in both copies of the gene, have elevated levels of homocysteine in their blood (hyperhomocysteinemia) resulting from the reduced activity of methylenetetrahydrofolate reductase.

    Researchers have studied MTHFR gene polymorphisms and hyperhomocysteinemia in individuals with neural tube defects and in their mothers, but it remains unclear how these variations affect the developing brain and spinal cord. The association with neural tube defects may be related to differences in the ability of methylenetetrahydrofolate reductase to process folate. While a shortage (deficiency) of this vitamin is an established risk factor for neural tube defects, there are many factors that can contribute to folate deficiency.

    MTHFR gene polymorphisms are common worldwide, with an estimated 25 percent of Hispanics and 10 to 15 percent of North American whites having the 677C>T polymorphism in both copies of the gene. Most people with MTHFR gene polymorphisms do not have neural tube defects, and their children are also typically unaffected.

    2.3. Spina bifida

    Some studies have found that polymorphisms in the MTHFR gene are also associated with a small increased risk of spina bifida, another common type of neural tube defect. When the spine forms in people with this condition, the bones of the spinal column do not close completely around the developing nerves of the spinal cord. As a result, part of the spinal cord may stick out through an opening in the spine, leading to permanent nerve damage.

    As described above, variations in the MTHFR gene generally result in hyperhomocysteinemia due to reduce activity of methylenetetrahydrofolate reductase and its ability to process folate. It is unclear how MTHFR gene changes might influence the development of neural tube defects. However, these variations are common in many populations worldwide. Most people with MTHFR gene polymorphisms do not have neural tube defects, nor do their children.

    2.4. Other disorders

    Polymorphisms in the MTHFR gene can alter or decrease the activity of methylenetetrahydrofolate reductase, leading to a mild increase of homocysteine in the blood (hyperhomocysteinemia). The two MTHFR gene polymorphisms that are the most common and the most frequently studied are 677C>T and a change that replaces the nucleotide adenosine with the nucleotide cytosine at position 1298 (written as 1298A>C).

    An increase in homocysteine levels caused by MTHFR gene polymorphisms have been studied as possible risk factors for a variety of common conditions. These include high blood pressure (hypertension), blood clots, pregnancy loss, psychiatric disorders, and certain types of cancer. Research indicates that individuals who have the 677C>T polymorphism on both copies of the MTHFR gene have an increased risk of developing vascular disease, including heart disease and stroke. The 677C>T polymorphism has also been suggested as a risk factor for cleft lip and palate, a birth defect in which there is a split in the upper lip and an opening in the roof of the mouth.

    Studies of MTHFR gene variations in people with these disorders have had mixed results, with associations found in some studies but not in others. Therefore, the role that changes in the MTHFR gene play in these disorders remains unclear. It is likely that additional factors influence the processing of homocysteine and that variations in homocysteine levels play a role in whether a person develops any of these conditions. A large number of genetic and environmental factors, most of which remain unknown, likely determine the risk of developing most common complex conditions.

    3. Other Names for This Gene

    • 5,10-methylenetetrahydrofolate reductase

    • 5,10-methylenetetrahydrofolate reductase (NADPH)

    • methylenetetrahydrofolate reductase (NAD(P)H)



    1. ACOG Practice Bulletin No. 197 Summary: Inherited Thrombophilias in Pregnancy.Obstet Gynecol. 2018 Jul;132(1):249-251. doi: 10.1097/AOG.0000000000002705.
    2. Bhargava S, Ali A, Parakh R, Saxena R, Srivastava LM. Higher incidence ofC677T polymorphism of the MTHFR gene in North Indian patients with vasculardisease. Vascular. 2012 Apr;20(2):88-95. doi: 10.1258/vasc.2011.oa0320.
    3. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants andcongenital anomalies: a HuGE review. Am J Epidemiol. 2000 May 1;151(9):862-77.Review.
    4. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidencefor MTHFR polymorphism testing. Genet Med. 2013 Feb;15(2):153-6. doi:10.1038/gim.2012.165.
    5. Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJ, Finglas PM,Jennings BA. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: A case-control study and meta-analysis. J Vasc Surg.2009 Mar;49(3):711-8. doi: 10.1016/j.jvs.2008.10.004.
    6. Kumar A, Kumar P, Prasad M, Sagar R, Yadav AK, Pandit AK, Jali VP, Pathak A.Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene(MTHFR gene) with ischemic stroke: a meta-analysis. Neurol Res. 2015Jul;37(7):568-77. doi: 10.1179/1743132815Y.0000000008.
    7. Levin BL, Varga E. MTHFR: Addressing Genetic Counseling Dilemmas UsingEvidence-Based Literature. J Genet Couns. 2016 Oct;25(5):901-11. doi:10.1007/s10897-016-9956-7.
    8. Liu F, Silva D, Malone MV, Seetharaman K. MTHFR A1298C and C677T PolymorphismsAre Associated with Increased Risk of Venous Thromboembolism: A RetrospectiveChart Review Study. Acta Haematol. 2017;138(4):208-215. doi: 10.1159/000480447.
    9. Moll S, Varga EA. Homocysteine and MTHFR Mutations. Circulation. 2015 Jul7;132(1):e6-9. doi: 10.1161/CIRCULATIONAHA.114.013311. Review.
    10. Sibani S, Christensen B, O'Ferrall E, Saadi I, Hiou-Tim F, Rosenblatt DS,Rozen R. Characterization of six novel mutations in the methylenetetrahydrofolatereductase (MTHFR) gene in patients with homocystinuria. Hum Mutat.2000;15(3):280-7.
    11. Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascularrisk. J Appl Genet. 2008;49(3):267-82. doi: 10.1007/BF03195624. Review.
    12. Trimmer EE. Methylenetetrahydrofolate reductase: biochemical characterization and medical significance. Curr Pharm Des. 2013;19(14):2574-93. Review.
    13. Urreizti R, Moya-García AA, Pino-Ángeles A, Cozar M, Langkilde A, Fanhoe U,Esteves C, Arribas J, Vilaseca MA, Pérez-Dueñas B, Pineda M, González V, ArtuchR, Baldellou A, Vilarinho L, Fowler B, Ribes A, Sánchez-Jiménez F, Grinberg D,Balcells S. Molecular characterization of five patients with homocystinuria dueto severe methylenetetrahydrofolate reductase deficiency. Clin Genet. 2010Nov;78(5):441-8. doi: 10.1111/j.1399-0004.2010.01391.x.
    14. Xie SZ, Liu ZZ, Yu JH, Liu L, Wang W, Xie DL, Qin JB. Association between the MTHFR C677T polymorphism and risk of cancer: evidence from 446 case-controlstudies. Tumour Biol. 2015 Nov;36(11):8953-72. doi: 10.1007/s13277-015-3648-z.
    15. Yadav U, Kumar P, Yadav SK, Mishra OP, Rai V. "Polymorphisms in folatemetabolism genes as maternal risk factor for neural tube defects: an updatedmeta-analysis". Metab Brain Dis. 2015 Feb;30(1):7-24. doi:10.1007/s11011-014-9575-7.
    16. Yan L, Zhao L, Long Y, Zou P, Ji G, Gu A, Zhao P. Association of the maternal MTHFR C677T polymorphism with susceptibility to neural tube defects inoffsprings: evidence from 25 case-control studies. PLoS One. 2012;7(10):e41689.doi: 10.1371/journal.pone.0041689.
    17. Zhang T, Lou J, Zhong R, Wu J, Zou L, Sun Y, Lu X, Liu L, Miao X, Xiong G.Genetic variants in the folate pathway and the risk of neural tube defects: ameta-analysis of the published literature. PLoS One. 2013 Apr 4;8(4):e59570. doi:10.1371/journal.pone.0059570. Print 2013.
    Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
    View Times: 171
    Entry Collection: MedlinePlus
    Revision: 1 time (View History)
    Update Date: 23 Dec 2020
    Table of Contents


      Are you sure to Delete?

      Video Upload Options

      Do you have a full video?
      If you have any further questions, please contact Encyclopedia Editorial Office.
      Guo, L. MTHFR Gene. Encyclopedia. Available online: (accessed on 27 September 2023).
      Guo L. MTHFR Gene. Encyclopedia. Available at: Accessed September 27, 2023.
      Guo, Lily. "MTHFR Gene" Encyclopedia, (accessed September 27, 2023).
      Guo, L.(2020, December 23). MTHFR Gene. In Encyclopedia.
      Guo, Lily. "MTHFR Gene." Encyclopedia. Web. 23 December, 2020.